ABSTRACT
PURPOSE: We investigated whether there is a difference in the treatment effect and pain during the treatment of meibomian gland dysfunction (MGD) with intense pulsed-light (IPL) between new light guide and conventional light guide. METHODS: We retrospectively reviewed medical records of 85 patients (170 eyes) who underwent IPL treatment of the upper and lower eyelids 3 times, at 3-week intervals, for MGD. Patients treated with the 6-mm or 8 × 15-mm cylindrical light guide were designated as group A or group B, respectively. The ocular surface disease index (OSDI), dry eye (DE), and MGD parameters were obtained before the first and after the third IPL treatments. Visual analog scale (VAS) scores were obtained at every IPL treatment. OSDI, DE, and MGD parameters and VAS scores were compared between the groups. RESULTS: VAS scores at the first, second, and third IPL treatments were lower in group A than in group B. OSDI, DE, and MGD parameters were improved after 3 IPL treatments in both groups. There were no significant differences in OSDI, DE symptoms, and MGD parameters between before the first IPL treatment and after the third IPL treatment between the groups. CONCLUSIONS: Using the new 6-mm cylindrical light guide for IPL treatment in patients with MGD induced less pain during treatment and had similar treatment effects to the conventional 8 × 15-mm light guide. The new 6-mm cylindrical light guide can be useful when treating patients with dark or hyperpigmented skin and for pediatric patients with low compliance.
Subject(s)
Eye Pain/therapy , Intense Pulsed Light Therapy/methods , Meibomian Gland Dysfunction/therapy , Meibomian Glands/diagnostic imaging , Pain Measurement/methods , Patient Compliance , Eye Pain/diagnosis , Eye Pain/etiology , Female , Follow-Up Studies , Humans , Male , Meibomian Gland Dysfunction/diagnosis , Meibomian Gland Dysfunction/metabolism , Middle Aged , Retrospective Studies , Tears/metabolismSubject(s)
Acupuncture Therapy/adverse effects , Eye Injuries, Penetrating/etiology , Retina/injuries , Retinal Hemorrhage/etiology , Retinal Perforations/etiology , Dry Eye Syndromes/therapy , Eye Injuries, Penetrating/diagnosis , Eye Pain/diagnosis , Eye Pain/etiology , Female , Humans , Retina/pathology , Retinal Hemorrhage/diagnosis , Retinal Perforations/diagnosisABSTRACT
Purpose: Ocular pain and discomfort are the most defining symptoms of dry eye disease. We determined the ability of topical progesterone to affect corneal sensitivity and brainstem processing of nociceptive inputs. Methods: Progesterone or vehicle gel was applied to the shaved forehead in male Sprague Dawley rats. As a site control, gel also was applied to the cheek on the side contralateral to corneal stimulation. Corneal mechanical thresholds were determined using the Cochet-Bonnet esthesiometer in intact and lacrimal gland excision-induced dry eye animals. Eye wipe behaviors in response to hypertonic saline and capsaicin were examined, and corneal mustard oil-induced c-Fos immunohistochemistry was quantified in the brainstem spinal trigeminal nucleus. Results: Progesterone gel application to the forehead, but not the contralateral cheek, increased corneal mechanical thresholds in intact and lacrimal gland excision animals beginning <30 minutes after treatment. Subcutaneous injection of the local anesthetic bupivacaine into the forehead region before application of progesterone prevented the increase in corneal mechanical thresholds. Furthermore, progesterone decreased capsaicin-evoked eye wipe behavior in intact animals and hypertonic saline evoked eye wipe behavior in dry eye animals. The number of Fos-positive neurons located in the caudal region of the spinal trigeminal nucleus after corneal mustard oil application was reduced in progesterone-treated animals. Conclusions: Results from this study indicate that progesterone, when applied to the forehead, produces analgesia as indicated by increased corneal mechanical thresholds and decreased nociceptive responses to hypertonic saline and capsaicin.
Subject(s)
Analgesics/administration & dosage , Corneal Diseases/prevention & control , Dry Eye Syndromes/complications , Eye Pain/prevention & control , Forehead , Progesterone/administration & dosage , Progestins/administration & dosage , Animals , Biomechanical Phenomena/physiology , Capsaicin/administration & dosage , Cornea/physiopathology , Corneal Diseases/etiology , Corneal Diseases/physiopathology , Disease Models, Animal , Eye Pain/etiology , Eye Pain/physiopathology , Gene Expression Regulation/physiology , Genes, fos/genetics , Male , Mustard Plant , Neurons/physiology , Pain Measurement , Plant Oils/administration & dosage , Rats , Rats, Sprague-DawleyABSTRACT
PURPOSE: To evaluate the advantage of peribulbar anesthesia in two quadrants (infero-temporal and upper nasal) vs single injection technique (infero-temporal) for scleral rhegmatogenous retinal detachment surgery (RRD). PATIENTS AND METHODS: 57 patients, aged between 33 and 75 years (57.01 ± 8.68), waiting for retinal detachment surgery, were randomized in two groups: a group S (29 patients), with single quadrant injection technique and a group C (28 patients) with two quadrants injection. Patients in Group S were injected in two quadrants with a 10 ml mixture containing Mepivacaine 2% 5 ml and Ropivacaine 0.75% 5 ml, with hyaluronidase 10 IU/ ml. Patients in group C were injected with the same anesthetic mixture in one quadrant. Number of additional injection, during surgery, in two groups, were reported. Pain was tested with VAS (Verbal Analogue Scale 0-10) after regional block, when muscles were insulated, during scleral buckling positioning, when conjunctive was closed and 6, 12, 24 hours after surgery. RESULTS: The need for a second peribulbar injection of anesthetic occurred in 9 patients of group C (32.14%); further injection was necessary in 1 patient (3.57%) of group S during scleral buckling (VAS = 7), statistically significant (p <0.05). Postoperative VAS 6 - 12 - 24 hours after surgery was not significant. CONCLUSIONS: The peribulbar anesthesia may be proposed in scleral surgery of retinal detachment; the injection in two quadrants secured solid and satisfactory anesthesia, increasing the outcome of retinal surgery in loco-regional anesthesia.
Subject(s)
Anesthesia, Local/methods , Anesthetics, Local/administration & dosage , Injections, Intraocular/methods , Retinal Detachment/surgery , Scleral Buckling , Adult , Aged , Eye Pain/etiology , Eye Pain/prevention & control , Female , Humans , Intraoperative Complications/etiology , Intraoperative Complications/prevention & control , Male , Mepivacaine/administration & dosage , Middle Aged , Pain, Postoperative/etiology , Ropivacaine/administration & dosageABSTRACT
BACKGROUND Necrotizing fasciitis (NF) of the orbit is a rare and deadly condition that requires prompt surgical and medical management to decrease morbidity and mortality. CASE REPORT Here we present an interesting case of an individual who developed fulminant NF of the left orbit requiring emergent surgical intervention, antibiotics, and subsequent hyperbaric oxygen therapy in an attempt to save the eye. CONCLUSIONS With an early and aggressive multifaceted approach using antibiotics, surgery, and hyperbaric oxygen it may be possible to preserve eye structure and function. Without treatment NF is a rapidly progressive condition and can result in significant morbidity.
Subject(s)
Eye Infections, Bacterial/therapy , Fasciitis, Necrotizing/therapy , Anti-Bacterial Agents/therapeutic use , Eye Pain/etiology , Female , Humans , Hyperbaric Oxygenation , Methicillin-Resistant Staphylococcus aureus/isolation & purification , Middle Aged , Staphylococcal Infections/diagnosis , Staphylococcal Infections/drug therapyABSTRACT
PURPOSE: This study aims to understand the effect of vitamin B12 deficiency on neuropathic ocular pain (NOP) and symptoms in patients with dry eye disease (DED). METHODS: Patients with severe DED (without receiving topical artificial tears treatment) and ocular pain were enrolled (n = 90). Patients with severe DED and vitamin B12 deficiency (group 1, n = 45) received parenteral vitamin B12 supplement + topical treatment (artificial tears treatment + cyclosporine), and patients with severe DED and normal serum vitamin B12 level (group 2, n = 45) received only topical treatment (artificial tears treatment + cyclosporine). Patients were evaluated by the ocular surface disease index (OSDI) questionnaire, 3rd question (have you experienced painful or sore eyes during last week?) score of OSDI as a pain determiner and pain frequency measure), tear break up time (TBUT), and Schirmer's type 1 test. We compared the groups' OSDI, TBUT, and Schirmer's test recordings at the first visit and after 12 weeks retrospectively. RESULTS: The OSDI score, 3rd OSDI question score, TBUT, and Schirmer's test results improved after 12 weeks (p < 0.001 for each group). The mean vitamin B12 level at enrollment was 144.24 ±43.36 pg/ml in group 1 and 417.53 ±87.22 pg/ml in group 2. The mean vitamin B12 level in group 1 reached to 450 ±60.563 pg/ml after 12 weeks of treatment. The mean score changes between the groups were not statistically significant; however, the decrease in the OSDI questionnaire score (-30.80 ±5.24) and 3rd OSDI question score (-2.82 ±0.53) were remarkable in group 1 (Table 2). The mean TBUT increase was +7.98 ±2.90 s and Schirmer's test result increase was +12.16 ±2.01 mm in group 1. The mean TBUT increase was +6.18 ±1.49 s and Schirmer's test result increase was +6.71 ±1.47 mm in group 2. CONCLUSIONS: These findings indicate that vitamin B12 deficiency is related with NOP. It may be important to consider measuring the serum vitamin B12 level in patients with severe DED presenting with resistant ocular pain despite taking topical treatment.
Subject(s)
Dry Eye Syndromes/drug therapy , Eye Pain/drug therapy , Lubricant Eye Drops/administration & dosage , Vitamin B 12 Deficiency/complications , Vitamin B 12/administration & dosage , Administration, Topical , Adult , Chronic Pain , Dry Eye Syndromes/complications , Dry Eye Syndromes/metabolism , Eye Pain/etiology , Female , Follow-Up Studies , Humans , Male , Retrospective Studies , Treatment Outcome , Vitamin B 12/pharmacokinetics , Vitamin B 12 Deficiency/drug therapy , Vitamin B 12 Deficiency/metabolism , Vitamin B Complex/administration & dosage , Vitamin B Complex/pharmacokineticsABSTRACT
Retinoids are compounds chemically related to vitamin A, which are frequently used in dermatological practice (1). They are characterized by numerous mechanisms of action leading to normalization of keratinocyte proliferation and maturation. They have anti-seborrhoeic, immunomodulatory and anti-inflammatory effects (1, 2). A number of side effects to retinoid treatment have been recorded; one group of such side effects relates to eyes and vision. Dry eye syndrome and blepharoconjunctivitis are the most common side effects, appearing in 20-50 % of patients treated with retinoids. They often contribute to the occurrence of other side-effects such as eye discomfort and contact lens intolerance. Due to the widespread use in clinical practice, the adverse effects, including ocular side effects, should be studied. To confirm the variety of adverse effects of retinoids, several case reports of rare side-effects are presented.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/adverse effects , Dermatologic Agents/adverse effects , Eye Diseases/chemically induced , Retinoids/adverse effects , Vision, Ocular/drug effects , Acne Vulgaris/drug therapy , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Conjunctivitis/chemically induced , Conjunctivitis/physiopathology , Dermatologic Agents/therapeutic use , Drug Monitoring , Dry Eye Syndromes/chemically induced , Dry Eye Syndromes/physiopathology , Eye Diseases/physiopathology , Eye Pain/etiology , Humans , Practice Guidelines as Topic , Retinoids/therapeutic useABSTRACT
PURPOSE: This case study reports on 2 novel neuromodulatory approaches in the management of a particularly recalcitrant case of corneal neuropathic pain. METHODS: Report of a case RESULTS: : A 32-year-old woman presented with intractable bilateral dry eye-like symptoms and corneal neuropathic pain after undergoing laser in situ keratomileusis surgery. Extensive ocular and systemic therapies were unsuccessful. Implantation of an electrode for the electrical stimulation of the trigeminal ganglion resulted in complete resolution of symptoms, but pain recurred after lead migration. Implantation of an intrathecal infusion system for fentanyl and bupivacaine delivery at the C1-C2 level resulted in control of her symptoms with excellent pain relief for more than 1 year. CONCLUSIONS: Electrical stimulation of the trigeminal ganglion and a high cervical intrathecal pain pump can be used in the management of corneal neuropathic pain unresponsive to ocular and systemic approaches.
Subject(s)
Bupivacaine/administration & dosage , Corneal Diseases/therapy , Drug Delivery Systems , Electric Stimulation Therapy , Fentanyl/administration & dosage , Trigeminal Ganglion/physiology , Trigeminal Neuralgia/therapy , Adult , Analgesics, Opioid/administration & dosage , Anesthetics, Local/administration & dosage , Combined Modality Therapy , Corneal Diseases/etiology , Dry Eye Syndromes/etiology , Dry Eye Syndromes/therapy , Electrodes, Implanted , Eye Pain/etiology , Eye Pain/therapy , Female , Humans , Infusions, Spinal , Keratomileusis, Laser In Situ/adverse effects , Microscopy, Confocal , Recurrence , Trigeminal Neuralgia/etiologyABSTRACT
OBJECTIVES: Thermal pulsation (LipiFlow) has been advocated for meibomian gland dysfunction (MGD) treatment and was found useful. We aimed to evaluate the efficacy and safety of thermal pulsation in Asian patients with different grades of meibomian gland loss. METHODS: A hospital-based interventional study comparing thermal pulsation to warm compresses for MGD treatment. Fifty patients were recruited from the dry eye clinic of a Singapore tertiary eye hospital. The ocular surface and symptom were evaluated before treatment, and one and three months after treatment. Twenty-five patients underwent thermal pulsation (single session), whereas 25 patients underwent warm compresses (twice daily) for 3 months. Meibomian gland loss was graded using infrared meibography, whereas function was graded using the number of glands with liquid secretion. RESULTS: The mean age (SD) of participants was 56.4 (11.4) years in the warm compress group and 55.6 (12.7) years in the thermal pulsation group. Seventy-six percent of the participants were female. Irritation symptom significantly improved over 3 months in both groups (P<0.01), whereas tear breakup time (TBUT) was modestly improved at 1 month in only the thermal pulsation group (P=0.048), without significant difference between both groups over the 3 months (P=0.88). There was also no significant difference in irritation symptom, TBUT, Schirmer test, and gland secretion variables between patients with different grades of gland loss or function at follow-ups. CONCLUSIONS: A single session of thermal pulsation was similar in its efficacy and safety profile to 3 months of twice daily warm compresses in Asians. Treatment efficacy was not affected by pretreatment gland loss.
Subject(s)
Dry Eye Syndromes/therapy , Eyelid Diseases/therapy , Hyperthermia, Induced/methods , Meibomian Glands , Adult , Aged , Dry Eye Syndromes/etiology , Dry Eye Syndromes/pathology , Dry Eye Syndromes/physiopathology , Eye Pain/etiology , Eyelid Diseases/complications , Female , Humans , Linear Models , Male , Meibomian Glands/metabolism , Meibomian Glands/pathology , Meibomian Glands/physiopathology , Middle Aged , Prospective Studies , Tears/metabolismABSTRACT
OBJECTIVES: The purpose of this study was to determine the clinical impact of using SYSTANE BALANCE Lubricant Eye Drops (Alcon, Fort Worth, TX), an oil-in-water emulsion, as a rewetting eye drop in symptomatic contact lens wearers. METHODS: Subjects who had previously experienced contact lens discomfort (CLD), with a mean lens wearing history of 18.6±12.8 years, were randomly assigned to use a Test (SYSTANE BALANCE Lubricant Eye Drops; n=76) or control (habitual nonlipid contact lens rewetting eye drop; n=30) drop over their contact lenses within 5 min of lens insertion and then subsequently at 2 hr intervals up to a maximum of 4 drops per eye daily for a 1-month period. Assessments of subjective comfort, comfortable wearing time, lid wiper epitheliopathy (LWE), and corneal staining were conducted at baseline and after 1 month, after 6 hr of lens wear. RESULTS: Comfort, wearing time, LWE, and corneal staining all showed statistically significant improvements in the test group using SYSTANE BALANCE Lubricant Eye Drops at the 1-month visit compared with baseline data (all P<0.01) and compared with the control group at the 1-month visit (P<0.01, P=0.01, P<0.01, and P=0.03, respectively). CONCLUSIONS: The use of SYSTANE BALANCE Lubricant Eye Drops as a rewetting drop in a group of wearers who experienced symptoms of CLD improved subjective comfort scores, increased comfortable wearing time, and reduced signs of LWE and corneal staining, when compared with the use of non-lipid-containing contact lens rewetting eye drops.
Subject(s)
Contact Lenses/adverse effects , Dry Eye Syndromes/drug therapy , Eye Pain/drug therapy , Lubricants/therapeutic use , Ophthalmic Solutions/therapeutic use , Adult , Aged , Dry Eye Syndromes/etiology , Emulsions/chemistry , Eye Pain/etiology , Female , Humans , Lubricants/chemistry , Male , Middle Aged , Ophthalmic Solutions/chemistry , Patient Satisfaction , Prospective Studies , Young AdultABSTRACT
PURPOSE: To assess the tolerability and outcomes of laser treatment for retinopathy of prematurity (ROP) under sub-tenon anaesthetic with oral or rectal sedation using a reliable, multidimensional, and internationally accepted tool for assessment of neonatal pain. METHODS: Sixty-two babies have had ROP laser treatment in our neonatal unit in the 7-year interval between 1 March 2005 and 28 February 2012; 44% (27 of the 62) were performed using sub-tenon anaesthesia. Pain scores were routinely assessed using the Neonatal Pain Agitation and Sedation Scale (N-PASS) every 10 min during laser treatment. The outcome and requirement for re-treatment in this group was compared with that in the intravenous sedation group. RESULTS: Pain scores were available in 19 of the 27 babies treated under sub-tenon anaesthesia. The mean pain score during treatment was 2.7 (SD ± 1.7, range 0.5-6.2). There was no statistically significant correlation between the mean pain score and duration of treatment (Spearman correlation coefficient (ρ) = 0.31; P = 0.09), number of laser burns (ρ = 0.32; P = 0.09), or post-menstrual age of the baby at the time of treatment (ρ = 0.38; P = 0.052). Treatments performed under sub-tenon anaesthesia were as successful as those performed under intravenous sedation. The mean pain scores during laser treatment under sub-tenon anaesthesia in our study were lower than those previously reported during ROP screening or heel-stick procedure.Conclusion Our study demonstrated that sub-tenon anaesthesia with oral or rectal sedation provides sufficient pain control for laser treatment for ROP without the need or risks of intravenous sedation and intubation.
Subject(s)
Anesthesia, Local/methods , Eye Pain/etiology , Laser Coagulation , Pain Measurement , Retinopathy of Prematurity/surgery , Acetaminophen/administration & dosage , Analgesics, Non-Narcotic/administration & dosage , Anesthetics, Local/administration & dosage , Birth Weight , Chloral Hydrate/administration & dosage , Conscious Sedation/methods , Gestational Age , Humans , Hypnotics and Sedatives/administration & dosage , Infant , Infant, Newborn , Intensive Care Units, Neonatal , Tenon Capsule , Treatment OutcomeABSTRACT
PURPOSE: To describe new affected individuals of Franceschetti's original pedigree of hereditary recurrent erosion and to classify a unique entity called Franceschetti corneal dystrophy. DESIGN: Observational case series. METHODS: Slit-lamp examination of 10 affected individuals was conducted. Biomicroscopic examinations were supplemented by peripheral corneal biopsy in 1 affected patient with corneal haze. Tissue was processed for light and electron microscopy and immunohistochemistry was performed. DNA analysis was carried out in 12 affected and 3 nonaffected family members. RESULTS: All affected individuals suffered from severe ocular pain in the first decade of life, attributable to recurrent corneal erosions. Six adult patients developed bilateral diffuse subepithelial opacifications in the central and paracentral cornea. The remaining 4 affected individuals had clear corneas in the pain-free stage of the disorder. Histologic and immunohistochemical examination of the peripheral cornea in a single patient showed a subepithelial, avascular pannus. There was negative staining with Congo red. DNA analysis excluded mutations in the transforming growth factor beta-induced (TGFBI) gene and in the tumor-associated calcium signal transducer 2 (TACSTD2) gene. CONCLUSION: We have extended the pedigree of Franceschetti corneal dystrophy and elaborated its natural history on the basis of clinical examinations. A distinctive feature is the appearance of subepithelial opacities in adult life, accompanied by a decreased frequency of recurrent erosion attacks. Its clinical features appear to distinguish it from most other forms of dominantly inherited recurrent corneal erosion reported in the literature.
Subject(s)
Corneal Dystrophies, Hereditary/complications , Adult , Aged , Aged, 80 and over , Antigens, Neoplasm/genetics , Biomarkers/metabolism , Biopsy , Cadherins/metabolism , Cell Adhesion Molecules/genetics , Child , Chondroitin/metabolism , Claudins/metabolism , Corneal Dystrophies, Hereditary/genetics , Corneal Dystrophies, Hereditary/metabolism , Corneal Opacity/etiology , DNA Mutational Analysis , Decorin/metabolism , Dermatan Sulfate/metabolism , Extracellular Matrix Proteins/genetics , Extracellular Matrix Proteins/metabolism , Eye Pain/etiology , Female , Humans , Immunohistochemistry , Male , Pedigree , Recurrence , Transforming Growth Factor beta/genetics , Transforming Growth Factor beta/metabolismABSTRACT
PURPOSE: To promote awareness and prevention of ocular damage that can occur during Intense Pulsed Light (IPL) treatments of the periocular areas. METHODS: A retrospective chart review was conducted of 2 cases involving ocular damage following IPL procedures that were treated at Bascom Palmer Eye Institute for ocular complications. Routine data were collected during ophthalmic examinations. RESULTS: Case 1: A 36-year-old female presented with eye pain, marked pupillary constriction, and anterior uveitis an hour after receiving IPL treatment to the face. Within 1 month, the damage had progressed to posterior synechiae and iris transillumination defects. She continues to have pain and severe photophobia due to permanent iris atrophy and transillumination that have persisted for years. Case 2: A 27-year-old female presented with severe eye pain, vision disturbances, pupillary defects, and anterior uveitis 3 days after IPL of an eyelid freckle. At 2 months follow up, the iris and pupillary defects remain permanent. The patient continues to suffer from photophobia and pain. CONCLUSIONS: The pigmented iris absorbs light in the same wavelength range of IPL, thus remaining vulnerable to IPL exposure, especially when applied to the periocular area. The fact that IPL is not a laser may give people a false sense of security regarding damage to the eye. The cases presented give evidence that periorbital IPL treatment may permanently affect pigmented intraocular structures. It is imperative for treating physicians to be aware of these hazards and to use appropriate eye protection to prevent ocular damage.
Subject(s)
Eye Pain/etiology , Phototherapy/adverse effects , Pupil Disorders/etiology , Radiation Injuries/etiology , Uveitis, Anterior/etiology , Adult , Eye Pain/drug therapy , Eyelid Diseases/therapy , Facial Dermatoses/therapy , Female , Glucocorticoids/administration & dosage , Humans , Melanosis/therapy , Ointments , Ophthalmic Solutions/administration & dosage , Pupil Disorders/drug therapy , Radiation Injuries/drug therapy , Retrospective Studies , Uveitis, Anterior/drug therapyABSTRACT
A 31-year-old woman underwent an evisceration of her blind, painful right eye with placement of an aluminum oxide orbital implant. Histopathologic assessment revealed functional hematopoietic bone marrow, confirmed by immunohistochemistry, within osseous metaplasia of the retinal pigment epithelium. This finding is exceedingly rare, with few cases reported in the English literature. This report raises numerous questions, including the association between pain and hematopoietic bone marrow formation, the potential benefits of hematopoietic bone marrow in the eye, and the molecular biologic basis for this rare phenomenon.